Alamar Biosciences, Inc. 8-K

What Happened

• Alamar Biosciences, Inc. filed an 8-K on July 15, 2026 reporting that board member Ian Ratcliffe passed away on July 5, 2026. Mr. Ratcliffe had served as an independent director since February 2024.
• Following his passing, the Board reduced the number of authorized directors to five and appointed Nicholas Naclerio, Ph.D., to the Board’s Audit Committee.

Key Details

• Ian Ratcliffe, independent director since Feb 2024, died July 5, 2026.
• Board decreased authorized director count to five (date: post-Ratcliffe’s passing).
• Nicholas Naclerio, Ph.D., was added to the Audit Committee.
• Disclosure was made in a Form 8-K filed July 15, 2026.

Why It Matters

• This is a governance change: the loss of an independent director and a change in board composition can affect oversight and corporate governance.
• Appointment to the Audit Committee is material for investors because the committee oversees financial reporting and controls; adding Dr. Naclerio may affect that oversight.
• The filing does not report changes to executive officers, financial results, or transactions — it is a board-level personnel and committee update.